Ivor Douglas, MD
Critical Care Medicine · Denver, CONPI 1881617173
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,842 of the $23,752 with a category attached, or 62.5%. Baxter Healthcare accounts for 99.6% of it on its own, with 3 other manufacturers making up the rest. Among critical care medicine clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $659.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$24K
- Dompe US, Inc.$65
- Insmed, Inc.$16
- Gilead$12
Across 275 payments — averaging $6091.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$536K
- Genentech, Inc.$388K
- Baxter Healthcare$383K
- Dompe Farmaceutici S.p.a.$363K
- Pfizer$5K
What the payments were for
- Consulting fees$14,84262%
- Speaking & faculty fees$1,1855%
- Travel & lodging$4,25018%
- Food & beverage$6473%
- Education$2,82812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 33 | $23,658 |
| Dompe US, Inc. | 1 | $65 |
| Insmed, Inc. | 1 | $16 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,752 in reported general payments places this provider in the 90th percentile of 141 critical care medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,185 |
| Azithromycin | 13 | $394 |
| Omeprazole | 15 | $65 |
| Prednisone | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Denver
- Gregory CosgroveDenver$46K
- Walter ConwellDenver$42K
- David HsiaDenver$38K
- Jennifer Faber GerlingDenver$30K
- Edward ChanDenver$6K
- Kenneth Lyn KewDenver$4K
- Ikue NakayamaDenver$3K
- Andi HudlerDenver$2K
- Patrick HumeDenver$1K
- Anuj MehtaDenver$888
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.